Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 256-266 , April 2009

Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review

  • José Paulo Araújo, MD

      Affiliations

    • Heart Failure Clinic, Serviço de Medicina Interna, Hospital S. João, Unidade I&D Cardiovascular do Porto, Porto, Portugal
    • Corresponding Author InformationReprint requests: José Paulo Araújo, MD, Heart Failure Clinic, Serviço de Medicina Interna, Hospital S. João, 4202-451 Porto, Portgual.
    • ,
  • Patricia Lourenço, MD

      Affiliations

    • Heart Failure Clinic, Serviço de Medicina Interna, Hospital S. João, Unidade I&D Cardiovascular do Porto, Porto, Portugal
    • ,
  • Ana Azevedo, MD, PhD

      Affiliations

    • Heart Failure Clinic, Serviço de Medicina Interna, Hospital S. João, Unidade I&D Cardiovascular do Porto, Porto, Portugal
    • Serviço de Higiene e Epidemiologia, Universidade do Porto, Porto, Portugal
    • ,
  • Fernando Friões, MD

      Affiliations

    • Heart Failure Clinic, Serviço de Medicina Interna, Hospital S. João, Unidade I&D Cardiovascular do Porto, Porto, Portugal
    • ,
  • Francisco Rocha-Gonçalves, MD, PhD

      Affiliations

    • Heart Failure Clinic, Serviço de Medicina Interna, Hospital S. João, Unidade I&D Cardiovascular do Porto, Porto, Portugal
    • ,
  • António Ferreira, MD, PhD

      Affiliations

    • Heart Failure Clinic, Serviço de Medicina Interna, Hospital S. João, Unidade I&D Cardiovascular do Porto, Porto, Portugal
    • ,
  • Paulo Bettencourt, MD, PhD

      Affiliations

    • Heart Failure Clinic, Serviço de Medicina Interna, Hospital S. João, Unidade I&D Cardiovascular do Porto, Porto, Portugal

Received 12 August 2008 ,Revised 26 September 2008 ,Accepted 24 October 2008.

References 

  1. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med. 1990;223:236–241
  2. Bozkurt B, Kribbs S, Clubb FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodelling in rats. Circulation. 1998;97:1382–1391
  3. Steele IC, Nugent AM, Maguire S, et al. Cytokine profile in chronic cardiac failure. Eur J Clin Invest. 1996;26:1018–1022
  4. Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac specific over expression of tumor necrosis factor-α. Circ Res. 1997;81:627–635
  5. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation. 1999;100:999–1088
  6. Paulus WJ. How are cytokines activated in heart failure?. Eur J Heart Fail. 1999;1:309–312
  7. Yamauchi-Takihara K, Ihara Y, Ogata A, et al. Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation. 1995;91:1520–1524
  8. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168
  9. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126
  10. D'Amore PJ. Evolution of C-reactive protein as a cardiac risk factor. Lab Med. 2005;36:234–238
  11. Kimberly MM, Vesper HW, Caudill SP, et al. Standardization of immunoassays for measurement of high-sensitivity C-reactive protein. Clin Chem. 2003;49:611–616
  12. Ridker PM. C-reactive protein and risks of future myocardial infarction and thrombotic stroke. Eur Heart J. 1998;191–193
  13. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary interventions. Circulation. 2001;104:992–997
  14. Strandberg TE, Tilvis RS. C-reactive protein, cardiovascular risk factors and mortality in a prospective study in the elderly. Arterioscler Thromb Vasc Biol. 2000;20:1057–1060
  15. Anan F, Masaki T, Umeno Y, et al. Correlations of high-sensitivity C-reactive protein and atherosclerosis in Japanese type 2 diabetic patients. Eur J Endocrinol. 2007;157:311–317
  16. Werdan K. The activated immune system in congestive heart failure—from dropsy to the cytokine paradigm. J Intern Med. 1998;243:87–92
  17. Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann Pharmacother. 2004;38:110–118
  18. Matsumori A. Anti-inflammatory therapy for heart failure. Curr Opin Pharmacol. 2004;4:171–176
  19. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2000;35:1628–1637
  20. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation. 2003;107:1486–1491
  21. Cesari M, Penninx BW, Newman AB, et al. Inflammatory markers and onset of cardiovascular events. Results from the Health ABC Study. Circulation. 2003;108:2317–2
  22. Kardys I, Knetsch AM, Bleumink GS, et al. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J. 2006;152:514–520
  23. Pietilla KO, Harmoinen AP, Jokinitty J, et al. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1996;17:1345–1349
  24. Berton G, Cordiano R, Palmieri R, et al. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J. 2003;145:1094–1101
  25. Suleiman M, Aronson D, Reisner SA, et al. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med. 2003;115:695–701
  26. Suleiman M, Khatib R, Agmon Y, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction. Predictive role of C-reactive protein. J Am Coll Cardiol. 2006;47:962–968
  27. Scirica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007;53:1800–1807
  28. Bursi F, Weston SA, Killian JM, et al. C-reactive protein and heart failure after myocardial infarction in the community. Am J Med. 2007;120:616–622
  29. Kavsak PA, MacRae AR, Newman AM, et al. Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. Clin Biochem. 2007;40:326–329
  30. Hartford M, Wiklund O, Mattsson Hulten L, et al. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med. 2007;262:526–536
  31. Mielniczuk LM, Pfeffer MA, Lewis EF, et al. Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. Am Heart J. 2008;155:725–731
  32. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein and B-type natriuretic peptide. Circulation. 2002;105:1760–1763
  33. Sabatine MS, Morrow DA, Jablonski KA, et al. Prognostic significance of the Centers for disease control/American Heart Association high sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007;115:1528–1536
  34. Williams ES, Shah SJ, Ali S, et al. C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study. Eur J Heart Fail. 2008;10:63–69
  35. Campbell DJ, Woodward M, Chalmers JP, et al. Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease. Hypertension. 2005;45:69–74
  36. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure. Prognostic value and the effect of valsartan. Circulation. 2005;112:1428–1434
  37. Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931–938
  38. Xue C, Feng Y, Wo J, et al. Prognostic value of high-sensitivity C-reactive protein in patients with chronic heart failure. N Z Med J. 2006;119:U2314
  39. Windram JD, Loh PH, Rigby AS, et al. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J. 2007;153:1048–1055
  40. Win WH, Chen JW, Feng AN, et al. Multimarker approach to risk stratification among patients with advanced chronic heart failure. Clin Cardiol. 2007;30:397–402
  41. Tang W, Shrestha K, Lente F, et al. Usefulness of C-reactive protein and left ventricular diastolic performance for prognosis in patients with left ventricular systolic heart failure. Am J Cardiol. 2008;101:370–373
  42. Tanner H, Mohacsi P, Fuller-Bicer GA, et al. Cytokine activation and disease progression in patients with stable moderate chronic heart failure. J Heart Lung Transplant. 2007;26:622–629
  43. Lamblin N, Mouquet F, Hennache B, et al. High-sensitivity c-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J. 2005;26:2245–2250
  44. Chirinos JA, Zambrano JP, Chakko S, et al. Usefulness of C-reactive protein as an independent predictor of death in patients with ischaemic cardiomyophaty. Am J Cardiol. 2005;95:88–90
  45. Kaneko K, Kanda T, Yamauchi Y, et al. C-reactive protein in dilated cardiomyophaty. Cardiology. 1999;9:215–219
  46. Ronnow BS, Reyna SP, Muhlestein JB, et al. C-reactive protein predicts death in patients with non-ischemic cardiomyophaty. Cardiology. 2005;104:196–201
  47. Lamarter F, Grimm W. Predictive value of high-sensitivity C-reactive protein in patients with idiopathic dilated cardiomyophaty. PACE. 2005;28:233–236
  48. Ishikawa C, Tsutamoto T, Fujii M, et al. Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy. Circ J. 2006;70:857–3
  49. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, et al. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail. 2002;4:331–336
  50. Mueller C, Laule-Kilian K, Christ A, et al. Inflammation and long-term mortality in acute congestive heart failure. Am Heart J. 2006;151:845–850
  51. Siirilä-waris K, Lassus J, Melin J, et al. FINN-AKVA study group. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J. 2006;27:3011–3017
  52. Villacorta H, Masetto AC, Mesquita ET. C-reactive protein: an inflammatory marker with prognostic value in patients with decompensated heart failure. Arq Bras Cardiol. 2007;88:585–589
  53. Michowitz Y, Arbel Y, Wexler D, et al. Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol. 2008;125:347–351
  54. Frazier C, Alexander K, Newby L, et al. Associations of gender and aetiology with outcomes in heart failure with systolic dysfunction. A pooled analysis of 5 randomized trials. J Am Coll Cardiol. 2007;49:1450–1458
  55. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Canters for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  56. Hung J, Knuiman MW, Divitini ML, et al. Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am J Cardiol. 2008;101:193–198
  57. Lakoski SG, Cushman M, Criqui M, et al. gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152:593–598
  58. Khera A, McGuire DK, Murphy SA, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46:464–469
  59. Hussey LC, Hardin S. Sex-related differences in heart failure. Heart Lung. 2003;32:215–223
  60. Panagiotakos DB, Pitsavos C, Yannakoulia M, et al. The implication of obesity and central fat on markers of chronic inflammation: the ATTICA study. Atherosclerosis. 2005;183:308–315
  61. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy and incident coronary heart disease: prospective analysis from the women's health initiative observational study. JAMA. 2002;288:980–987
  62. Kushner I, Broder ML, Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest. 1978;61:235–242
  63. Heeschen C, Hamm CW, Bruemmer J, et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. J Am Coll Cardiol. 2000;35:1535–1542
  64. James SK, Armstrong P, Barnathan E, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol. 2003;41:916–924
  65. Lindahl B, Toss H, Siegbahn A, et al Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 200:343:1139–1147.
  66. Ferreiros ER, Boissonet CP, Pizarro R, Merletti PFG, Corrado G, Cagide A, et al. Independent prognostic value of elevated C-reactive protein in unstable angina Circulation. 1999;100:1958–1963
  67. Heinrich J, Schulte H, Schonfeld R, et al. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73:374–378
  68. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link?. Lancet. 1997;350:430–436
  69. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94:874–877
  70. Liuzzo G, Biasucci LM, Rebuzzi AG, et al. Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation. 1996;94:2373–2380
  71. Nian M, Lee P, Khaper N, et al. Inflammatory cytokines and postmyocardial infarction remodelling. Circ Res. 2004;94:1543–1553
  72. Venugopal SK, Deveraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens. 2005;14:33–37
  73. Verma S, Wang CH, Li SH, et al. A self –fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913–919
  74. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial. J Exp Med. 1999;190:1733–1740
  75. Elster SK, Braunwald E, Wood HF. A study of C-reactive protein in the serum of patients with congestive heart failure. Am Heart J. 1956;51:533–541
  76. Clark DJ, Cleman MW, Pfau SE, et al. Serum complement activation in congestive heart failure. Am Heart J. 2001;141:684–690
  77. Anker SD, von Haehling S. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464–470
  78. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  79. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  80. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–28
  81. Pepys MB, Hirschfield GM, Tennents GA, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1271–21
  82. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–2261
  83. Investigators GISSI-HF. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double blind, placebo-controlled trial. Lancet. 2008;
  84. Rauchhaus M, Coats AJ, Anker SD. The endotoxin-lipoprotein hypothesis. Lancet. 2000;356:930–933
  85. Morrow DA, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e365–e375
  86. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation. 2007;116:e99–e109

 No conflicts of interest and no sources of funding disclosed.

PII: S1071-9164(08)01054-3

doi: 10.1016/j.cardfail.2008.10.030

Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 256-266 , April 2009

Article Tools

* Image Usage & Resolution